Search Results

Displaying Results 1-25 of 724 "'RES'"

Jun 04, 2026, 04:35 ET World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA

Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer.  a systematic review and meta-analysis. Anticancer Res. May 2014;34(5):2079-85.Xu B, Wang JM. Epidemiological study of gastric cancer[J]. Chin J Cancer Prev Treat, 2006,13(1): 81-87.Chan

More news about: Innovent Biologics


Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30.Ahn

More news about: Amgen


Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30.Ahn

More news about: Amgen


Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526 – 1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther.

More news about: Amgen


Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin

More news about: Amgen


Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ

ukierunkowany na DLL3, wykazuje wysoką siłę działania i wrażliwość w przedklinicznych modelach drobnokomórkowego raka płuca). Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy (Uczenie przeciwciał

More news about: Amgen


Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30.Ahn

More news about: Amgen


Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO

DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr

More news about: Amgen


Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

https://www.ncbi.nlm.nih.gov/books/NBK431049/11 Hackett KL, et al. Impaired functional status in primary Sjögren's syndrome. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1760-4.12 Meijer JM, et al. Health-related quality of life, employment and disability in patients with

More news about: Johnson & Johnson


Jun 02, 2026, 09:00 ET Designed for Comfort, Built for Everyday Entertainment: Introducing the new motorola edge 2026 and moto buds 2

6mm Micro Planar Magnetic Drivers with Hi-Res audio support. This adds depth, fullness and details to users' anticipated albums, binge-worthy shows and niche podcasts. Consumers get realistic details and clarity with Hi-Res Audio and LHDC, while Dolby Atmos spatial sound18

More news about: Motorola Mobility, Inc


Jun 02, 2026, 08:33 ET Discover MGallery Collection's Debut in the Maldives, the V Villas Maldives at Mirihi - MGallery Collection

women.Villas start at $600 USD per night, and luxury suites are available from $2,100 per night. Bookings are now open.For high-res imagery, click

More news about: MGallery Hotel Collection


Jun 02, 2026, 07:00 ET Plot Raises $10M to Scale Social Video Intelligence for Marketing Teams at Fortune 500 Brands

investment research and to understand and grow the communities around our sports teams and leagues like Athlos, Angel City, and LA Golf Club."For high-res images of the Plot platform, screenshots, and logos, please visit this

More news about: Plot


Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30.Ahn

More news about: Amgen


Jun 01, 2026, 09:00 ET CND™ Unveils New SHELLAC™ System, Defining the Future of Nail Technology

Distributor Locator on CND.com to purchase. Suggested price for in-salon services range from $45-$55 ($55-$65 with nail artistry) depending upon location. Hi-res images can be found

More news about: CND™


Jun 01, 2026, 09:00 ET Redefine Everyday Comfort with Baseus Bowie MC2 Open-Ear Audio

for their high-resolution, balanced wireless audio with up to 3 times more detail than standard codecs, even within an open-ear design. Backed by Hi-Res certification, LDAC, custom 11mm dynamic drivers, SuperBass 3.0 technology, and upgraded BIAS Spatial Audio, it is designed to produce richer sound,

More news about: Baseus


Jun 01, 2026, 09:00 ET Alltäglicher Komfort neu definiert: die Open-Ear-Ohrhörer Bowie MC2 von Baseus

hochauflösenden, ausgewogenen kabellosen Klang mit bis zu dreimal mehr Details als bei Standard-Codecs empfohlen, selbst bei einem offenen Ohrdesign. Mit Hi-Res-Zertifizierung, LDAC, speziellen 11-mm-Dynamiktreibern, SuperBass 3.0-Technologie und aktualisiertem BIAS Spatial Audio erzeugen sie einen satteren Klang,

More news about: Baseus


Jun 01, 2026, 09:00 ET Redefine Everyday Comfort with Baseus Bowie MC2 Open-Ear Audio

for their high-resolution, balanced wireless audio with up to 3 times more detail than standard codecs, even within an open-ear design. Backed by Hi-Res certification, LDAC, custom 11mm dynamic drivers, SuperBass 3.0 technology, and upgraded BIAS Spatial Audio, it is designed to produce richer sound,

More news about: Baseus


Jun 01, 2026, 09:00 ET Une nouvelle définition du confort quotidien avec les écouteurs ouverts Bowie MC2 de Baseus

à haute résolution, qui propose jusqu'à trois fois plus de détails que les codecs standard malgré un design ouvert. Soutenus par la certification Hi-Res, le codec audio LDAC, des haut-parleurs dynamiques personnalisés de 11 mm, la technologie SuperBass 3.0 et la technologie d'audio spatial BIAS améliorée,

More news about: Baseus


Jun 01, 2026, 09:00 ET BRUICHLADDICH CELEBRATES 25 YEARS WITH THE RETURN OF YELLOW SUBMARINE III

2026.For more information on Bruichladdich Yellow Submarine III and Bruichladdich Distillery, visit us.bruichladdich.com.A selection of high-res images and product renders (© Bruichladdich Distillery) are available:

More news about: Bruichladdich


May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2025;31(13):2617-2627. doi:10.1158/1078-0432.CCR-25-00738 Große-Thie C, Maletzki C, Junghanss C, Schmidt K. Long-term survivor

More news about: Johnson & Johnson


May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833 9 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372),

More news about: Johnson & Johnson


May 29, 2026, 11:50 ET Concrete Corrosion Inhibitors Market to Reach USD 3.02 Billion by 2033, Driven by Infrastructure Durability Requirements, Corrosion Risk Mitigation, and Advanced Mixed/Polymer Formulations - Verified Market Research

content:https://www.prnewswire.com/news-releases/concrete-corrosion-inhibitors-market-to-reach-usd-3-02-billion-by-2033--driven-by-infrastructure-durability-requirements-corrosion-risk-mitigation-and-advanced-mixedpolymer-formulations--verified-market-research-302785779.htmlSOURCE

More news about: Verified Market Research


May 29, 2026, 08:03 ET 2G Energy obtiene el mayor pedido en la historia de la empresa y acelera la expansión de centros de datos en Norteamérica

https://mma.prnewswire.com/media/1701284/2G_High_Res_Logo_Logo.jpg FUENTE 2G Energy

More news about: 2G Energy


May 28, 2026, 17:18 ET Euhomy Helps Keep This Summer Chilled With Launch of Rock Plus and Rock Pro Smart Ice Makers

combining thoughtful design, smart functionality, and premium ice performance for today's home entertaining needs.For product spec sheets and hi-res images, please find the media kit HERE. For more information about Euhomy's products, visit www.euhomy.com.About

More news about: Euhomy


May 28, 2026, 16:00 ET Gumball 3000 Kicks Off 27th Annual Rally at Seminole Hard Rock Hotel & Casino Hollywood with a Spectacular Route from Miami to Mexico City

5-10Partnership with Hard Rock International Enters Fifth YearEditor's Note: Download high-res images

More news about: Hard Rock International


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.